Seth Baum, MD

Final Insights

Video content above is prompted by the following:

Are there any final insights you’d like to share regarding LDL-C and Lp(a) screening and management of high-risk cardiovascular patients?

Videos

Pediatric lipid screening is crucial for early detection and management of dyslipidemia, which can prevent cardiovascular diseases later in life. Current guidelines recommend universal lipid screening for children between ages 9-11 and 17-21, with selective screening for those with risk factors. However, implementation remains inconsistent due to barriers such as lack of awareness and time constraints in clinical practice. To improve uptake, strategies include integrating screening into routine pediatric visits, utilizing electronic health records for reminders, and educating healthcare providers and families about the importance and benefits of early lipid screening.

Panelists discuss how effective cardiovascular risk management requires comprehensive screening for both LDL-C and Lp(a), along with aggressive treatment strategies for high-risk patients.

Barriers Associated With Controlling LDL-C

What are some of the barriers associated with controlling LDL-C across clinicians, patients, payers, and policy makers (eg, failure of clinicians to intensify LLT, low patient understanding and adherence to therapy, high copays, restrictive prior authorization requirements, removal of LDL-C quality measure by NCQA-HEDIS)?

Panelists discuss how multiple systemic barriers impede optimal LDL-C control, including clinical inertia, patient adherence challenges, insurance restrictions, and the removal of key quality measures.

CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid

The primary prevention data with bempedoic acid from CLEAR-outcomes are exciting. Could you review the data and how you use BA in your practice?

Panelists discuss how the CLEAR-outcomes trial demonstrated bempedoic acid’s efficacy in primary prevention of cardiovascular events, informing its clinical implementation for patients with statin intolerance or inadequate LDL-C control.

Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk

What are some of the newer, nonstatin LLTs that are approved for lowering LDL-Cand reducing CVD risk (eg, inclisiran, alirocumab, evolocumab, bempedoic acid)?

Panelists discuss how newer nonstatin therapies, such as PCSK9 inhibitors (inclisiran, alirocumab, evolocumab) and bempedoic acid, offer additional options for LDL-C reduction and cardiovascular risk management.

Seth Baum, MD

Articles